Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Aanika Balaji WarnerMelinda HsuCheng Ting LinJosephine FelicianoKristen MarroneJulie R BrahmerPatrick M FordeChristine HannLei ZhengValerie LeePeter B IlleiSonye K DanoffKarthik SureshJarushka NaidooPublished in: Journal for immunotherapy of cancer (2021)
Steroid-refractory ICI-pneumonitis constituted 18.5% of referrals for multidisciplinary irAE care. Steroid-refractory ICI-pnuemonitis occurred early in patients' treatment courses, and most commonly exhibited a DAD radiographic pattern. Patients treated with IVIG alone demonstrated an improvement in both level-of-care and oxygenation requirements and had fewer fatalities (43%) from steroid-refractory ICI-pneumonitis when compared to treatment with infliximab (100% mortality).
Keyphrases
- healthcare
- end stage renal disease
- palliative care
- quality improvement
- chronic kidney disease
- type diabetes
- newly diagnosed
- ejection fraction
- rheumatoid arthritis
- interstitial lung disease
- cardiovascular events
- prognostic factors
- replacement therapy
- pain management
- chronic pain
- tandem mass spectrometry
- ulcerative colitis